More recently, others have integrated hK2 with intact, total, and free PSA to construct a “kallikrien-panel” that has been shown to improve the prediction of prostate cancer in previously unscreened men with an elevated PSA (>3 ng/mL) derived from the Rotterdam cohort of the ERSPC (European Randomized Study of Screening for Prostate Cancer) (Vickers et al. 2008). This evidence concerns the gene HK2 and Familial prostate cancer.